Welcome to our dedicated page for Aquestive Therapeutics SEC filings (Ticker: AQST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Looking for the story behind Aquestive Therapeutics鈥� film-based drug delivery breakthroughs? Our SEC filings hub connects the dots between headline-grabbing pipeline news and the hard numbers hidden in 10-K annual reports. With Stock Titan鈥檚 AI, understanding Aquestive Therapeutics SEC documents with AI means you can spot clinical-trial expenses, royalty revenue, and burn-rate trends without wading through jargon-heavy pages.
Need specific updates? AG真人官方-time alerts surface Aquestive Therapeutics Form 4 insider transactions real-time, so you see management鈥檚 moves as they happen. The same dashboard clarifies every Aquestive Therapeutics quarterly earnings report 10-Q filing, highlights cash-flow shifts, and provides concise Aquestive Therapeutics earnings report filing analysis. Material announcements get equal attention鈥攐ur summaries make each Aquestive Therapeutics 8-K material events explained in plain language.
For deeper dives, open any document and let the platform answer questions you鈥檇 normally send to an analyst:
- Aquestive Therapeutics insider trading Form 4 transactions 鈥� follow executive buy & sell patterns.
- Aquestive Therapeutics proxy statement executive compensation 鈥� unpack pay structures, option grants, and dilution risk.
- Aquestive Therapeutics annual report 10-K simplified 鈥� see timelines for CNS and anaphylaxis programs.
- Aquestive Therapeutics executive stock transactions Form 4 鈥� monitor confidence before trial readouts.
Whether you鈥檙e preparing a valuation model or simply checking risk factors, Stock Titan鈥檚 AI-powered summaries, expert context, and comprehensive coverage turn dense biotech disclosures into actionable insight鈥攏o PhD required.
Aquestive Therapeutics is a single-segment pharmaceutical company focused on alternative delivery technologies and a pipeline for severe allergic reactions and epinephrine prodrugs. For the six months ended June 30, 2025, total revenue fell to $18.7 million from $32.2 million a year earlier, driven by an 87% decline in license and royalty revenue tied to prior contract terminations. The company reported a $36.5 million net loss for the six-month period (loss per share $0.37), compared with a $15.6 million loss in the prior year period.
At June 30, 2025, cash and cash equivalents were $60.5 million, total assets $93.7 million, total liabilities $166.3 million, and stockholders鈥� deficit $(72.6) million. The company has $45.0 million of 13.5% senior secured notes with associated royalty obligations and recorded $50.0 million in proceeds from a prior monetization of future royalties. Equity issuance through an ATM generated ~$21.3 million in the six-month period. Management states existing cash, expense management and access to equity markets provide near-term liquidity for at least the next twelve months.
Aquestive Therapeutics announced a press release reporting its reported financial results for the second quarter ended June 30, 2025 and provided a business update. The press release and accompanying financial schedules are included as Exhibit 99.1 and are referenced in Item 2.02 of the Current Report.
The company also furnished investor presentations and a corporate presentation as Exhibits 99.2 and 99.3, stating those materials are available on the Events and Presentations page of its website. The filing clarifies that the disclosed materials are furnished and shall not be deemed to be "filed" for purposes of Section 18 of the Exchange Act.
In an 8-K filed on July 15, 2025, Aquestive Therapeutics (AQST) disclosed that Health Canada has granted the company a formal meeting to discuss a planned New Drug Submission (NDS) for its lead candidate, Anaphylm™ (epinephrine) Sublingual Film. The company also confirmed it has submitted an initial briefing book to the European Medicines Agency (EMA) and intends to file a Marketing Authorization Application (MAA) "as soon as possible."
Although the filing contains no financial figures, the regulatory milestones could significantly expand Anaphylm鈥檚 addressable market beyond the U.S., potentially accelerating future revenue once approvals are secured.
FAQ
What is the current stock price of Aquestive Therapeutics (AQST)?
What is the market cap of Aquestive Therapeutics (AQST)?
